Ascendiant Capital Rates Aytu BioPharma (AYTU) buy

Ascendiant Capital maintains a buy rating on Aytu BioPharma, setting a $14.5 price target, a 559.09% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ascendiant Capital rated Aytu BioPharma, Inc. ($AYTU) "buy" with a $14.50 price target on June 11, 2026.

Since the rating, $AYTU is up 5.5% after 1 week, down 0.5% after 1 month and down 6.8% to date (from the $2.19 close on Jun 11, 2026).

AYTU Aytu BioPharma, Inc.

$2.04 -26.35% year to date

Daily close · Oct 16, 2026

Key Points

Ascendiant Capital reiterated its buy rating on Aytu BioPharma, Inc. with a $14.5 price target on June 11, 2026.
Ascendiant Capital's $14.50 price target implies 559.09% upside from Aytu BioPharma, Inc.'s ($AYTU) current $2.20 share price.
Aytu BioPharma trades near $2.19 with a market cap of about $23.1 million and a 52-week range of $1.65 to $3.07.
Peer fund Diadema Partners LP increased its stake by 47,289 shares, bringing its total to 353,077 shares worth about $963,900.

Get $AYTU trade alerts by text

We text you when insiders, Congress or big funds trade $AYTU. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Aytu BioPharma, Inc. alert may contain errors. Disclosures

On June 11, 2026, Ascendiant Capital reiterated its buy rating on Aytu BioPharma, Inc. (NasdaqCM:AYTU). The firm set a price target of $14.5, while shares of Aytu BioPharma traded around $2.19.

Aytu BioPharma, Inc. Stock Up 3.8%

Shares of NasdaqCM:AYTU were trading near $2.19. Aytu BioPharma has a market cap of approximately $23.1 million. The stock has seen a 52-week low of $1.65 and a high of $3.07. Its 50-day moving average is $2.39, with a 200-day moving average of $2.38. The company has a forward P/E ratio of -28.67, reflecting its lack of profitability, and a debt-to-equity ratio of 62.08.

12-month forecast

$AYTU price target

Aytu BioPharma, Inc. daily closes and this analyst's $14.50 target. Not advice.

Recent Earnings

Aytu BioPharma reported revenue of $56.6 million, though it experienced a revenue decline of 32.7%. The company has a net margin of -60.17% and a return on equity of -97.42%. Its next earnings announcement is expected on May 14, 2025.

Other Institutional Activity in Aytu BioPharma

Diadema Partners LP increased its holdings by 47,289 shares, bringing its total to 353,077 shares valued at approximately $963,900. Meanwhile, Stonepine Capital Management, LLC reduced its position by 21,415 shares, leaving it with 792,289 shares worth about $2.16 million. Vanguard Capital Management LLC and Crown Advisors Management, Inc. both initiated new positions, acquiring 261,146 and 145,000 shares respectively.

Insider Buying and Selling at Aytu BioPharma, Inc.

Recent insider activity includes purchases by Abhinav Jain and Vivian Liu, each acquiring 10,000 shares on October 3, 2025. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On June 11, 2026, Ascendiant Capital maintained its buy rating on Aytu BioPharma with a $14.5 price target. The consensus among analysts is a strong buy, with a mean target price of $9.5, based on three analyst opinions.

About Aytu BioPharma

Aytu BioPharma, Inc. is a pharmaceutical company based in Denver, Colorado, focusing on the commercialization of novel therapeutics. The company offers a range of prescription products for ADHD and pediatric care, including Adzenys XR-ODT, Cotempla XR-ODT, and Metadate CD. Under the leadership of CEO Joshua R. Disbrow, the company employs 82 people.

Bottom Line

Ascendiant Capital's reiteration of its buy rating and $14.5 price target highlights ongoing interest in Aytu BioPharma despite its current trading price. Investors often track such analyst updates for potential insight into a company's future performance, although it's important to remember that these ratings reflect past data and may not indicate current conditions.